β2-adrenoceptor agonist 1

BALB/c (female, 6-8 weeks old)^[1]

100 μg/kg/day (228.9 nmol/kg/day); 200 μg/kg/day (458.5 nmol/kg/day)

inhalation; once daily; 15 days

At 100 μg/kg/day, compound C3 did not improve lung function in asthmatic mice.
At 200 μg/kg/day, compound C3 improved Peak Expiratory Flow (PEF), Maximal Mid-Expiratory Flow (MMEF), Dynamic Compliance (Cdyn), Forced Vital Capacity (FVC), and Forced Expiratory Volume in 0.1 s (FEV0.1) to levels comparable to the positive-control group.
Both 100 and 200 μg/kg/day compound C3 reduced total white blood cell count in bronchoalveolar lavage fluid (BALF).
Differential cell counting showed reductions in eosinophils, neutrophils, and lymphocytes in groups receiving compound C3 compared with the model group.
Compound C3 reduced IL-4, IL-5, and IL-13 levels in BALF, lung tissue, and serum, with the 200 μg/kg/day group showing efficacy comparable to the positive control.
Toluidine blue (HY-D0220) staining showed dose-dependent improvement in lung histopathology, and the 200 μg/kg/day group had a reduction in mast cell numbers comparable to the positive control.
H&E staining confirmed protective effects on lung histopathology; the 200 μg/kg/day group showed an effect comparable to the positive control.